Chanice Henry | 08/08/2017
                                    
                    
                                                Experts have urged that legislation on early access programs needs to be tightened to protect the seriously ill Through expanded early access programs (EAPs), terminally- ill patients that fit certain criteria will be allowed access to unauthorized drugs outside of a clinical trial.These programs aim to give dying patients ethical and controlled strategic access to potentially life- saving medicines before they gain approval.  However, the lack of clarity and harmonization of regional regul...
                    To continue reading this story Click Here
                                    
                            RECOMMENDED
Upcoming Events
Pharmaceutical Launch Excellence Summit
                            2 - 3 December, 2025
                            
 
                            UK
                            
                             Register Now |
                            View Agenda |
                            Learn More
                        
Pharma Contract Manufacturing
                            23 - 25 March 2026
                            
 
                            Mercure Hotel MOA Berlin, Germany
                            
                             Register Now |
                            View Agenda |
                            Learn More